Table 2.
Clinical characteristics in patients with a different q abnormality pattern.
| q ⩽ T1C | q > T1C | p value | |
|---|---|---|---|
| n | 23 | 28 | |
| Age, years (mean ± SD) | 60.09 ± 2.312 | 57.40 ± 2.061 | 0.490 |
| Sex (M/F, %) | 50/50 | 84/17 | 0.061 |
| Complete resection CE (% of patients) | 75 | 75 | n.s. |
| Gliadel use (%) | 56.25 | 70.8 | 0.486 |
| IDH-1 mutation (n) | 1 | 3 | 0.609 |
| MGMT methylation (n) | 9 | 11 | n.s. |
| Progression-free survival (days) | 53 | 287 | 0.001 |
| Overall survival (days) | 274 | 464 | 0.006 |
Patients with q abnormality areas smaller or equal to contrast-enhanced areas (q ⩽ T1C) are compared with patients with q abnormality areas larger than the contrast-enhanced areas for more than half of MRS voxel size (q > T1C).
CE, contrast enhanced; IDH-1, isocitrate dehydrogenase-1; MGMT, O6-methylguanine-deoxyribonucleic acid methyltransferase; MRS, magnetic resonance spectroscopy; n.s., not significant; SD, standard deviation; T1C, contrast-enhanced areas.